The RANK-L/RANK/osteoprotegerin (OPG) pathway plays a critical role in osteosarcoma, with studies indicating its involvement in tumor progression and potential as a therapeutic target (98–101). This evidence concerns the gene TNFRSF11B and neoplasm.